Apellis Pharmaceuticals (APLS) Acceptance of 24-month Filing in GA Marks 'Clearing Event' - Raymond James
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating and $123.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
